A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Second Generation Andexanet Alfa Administered to Healthy Subjects
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2017
At a glance
- Drugs Andexanet alfa (Primary) ; Apixaban; Edoxaban; Enoxaparin sodium; Rivaroxaban
- Indications Haemorrhage
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Portola Pharmaceuticals
- 06 Sep 2017 Planned End Date changed from 31 Aug 2017 to 30 Sep 2017.
- 06 Sep 2017 Planned primary completion date changed from 31 Aug 2017 to 30 Sep 2017.
- 06 Sep 2017 Status changed from recruiting to active, no longer recruiting.